Back to discover
Drug

Deferiprone

Approved · EMA
Emerging researchLate-stage development
Also known as Ferriprox, Deferiprona, Défériprone, 1,2-Dimethyl-3-hydroxypyrid-4-one+2 more

Ferriprox, Deferiprona, Défériprone, 1,2-Dimethyl-3-hydroxypyrid-4-one, 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone, Deferipronum.

RxNorm11645ChEMBLCHEMBL70927ATCV03AC02UNII2BTY8KH53L
1
Research papers
2
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Early Detection and Management of Cardiac Iron Overload in Sickle Cell Disease Using Multimodal Imaging for Improved Clinical Outcomes

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Clinical trial2026-04-08Results expected Q1 2029 · ClinicalTrials.gov

Long-term Iron Chelation in the Prevention of Secondary Remote Degeneration After Stroke

Clinical trial2025-04-22Terminated · ClinicalTrials.gov

Ferrochelating Treatment in Patients Affected by "Neurodegeneration With Brain Iron Accumulation" (NBIA)

Clinical trial2024-12-01Primary completion · ClinicalTrials.gov

Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer.

Research2024-10-01Cancer discovery

Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone

Clinical trial2024-05-06Completed · ClinicalTrials.gov

A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease

Clinical trial2024-04-10Results posted · ClinicalTrials.gov

Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia

Clinical trial2024-03-15Results posted · ClinicalTrials.gov

An N of One Clinical Trial to Pilot the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment

Clinical trial2023-04-01Withdrawn · ClinicalTrials.gov

Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies

Clinical trial2021-05-04Results posted · ClinicalTrials.gov

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone"

Clinical trial2020-09-22Completed · ClinicalTrials.gov

Approval: Ferriprox (EMA)

Regulatory1999-08-25EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Deferiprone
Aliases & brands
FerriproxDeferipronaDéfériprone1,2-Dimethyl-3-hydroxypyrid-4-one3-Hydroxy-1,2-dimethyl-4(1H)-pyridoneDeferipronum
RxNorm CUI
11645
ChEMBL ID
CHEMBL70927
ATC codes
V03AC02
UNII
2BTY8KH53L
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
1999-08-25
Latest approval
1999-08-25
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
1999-08-25Approval
Approval: Ferriprox (EMA)
Indication: Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.… Show full indication

Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

37 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
37
registered trials across all phases
LATEST COMPLETION 2024
2
Active studies
2
Recruiting
19
Late-stage (III+)
25
Completed
10
Discontinued
PHASE DISTRIBUTIONn = 37
Early Phase 11Phase 15Phase 1 / 21Phase 211Phase 2 / 34Phase 36Phase 48Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia

CompletedPH IVChiesi Canada Corpn=642020

Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias

TerminatedPH IVApoPharman=1342019

The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias

TerminatedPH IVApoPharman=2302019

An Open-label Study to Compare the Pharmacokinetic Profiles of a Single Dose of Ferriprox in Subjects With Impaired Renal Function and Healthy Volunteers

CompletedPH IVApoPharman=322013

A Double-Blind, Randomized, Crossover, Thorough QT/QTc Trial to Evaluate the Potential of Deferiprone to Prolong the QT Interval in Healthy Subjects

CompletedPH IVApoPharman=502013

Recent completions

Trials that read out recently, adding to the completed evidence base.

Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone

CompletedPH II/IIIUniversity Hospital, Lillen=3722024

Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia

CompletedPH IVChiesi Canada Corpn=642020

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone"

CompletedPH IIUniversity Hospital, Lillen=3722020

Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis

CompletedN/AUniversity Hospital, Lillen=902020

A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease

CompletedPH IIApoPharman=1402019

The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome

CompletedPH IISheba Medical Centern=192018

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes3
Immunity, Innate1Iron Chelating Agents1Ovarian Neoplasms1
Journals, researchers & institutions
Top journals
  • Cancer discovery1
Leading researchers
  • Awasthi D1
  • Cantillo E1
  • Chae CS1
  • Chapman-Davis E1
  • Cloonan SM1
  • Cubillos-Ruiz JR1
  • Emmanuelli A1
  • Frey MK1
Leading institutions
free-text, unnormalised
  • Caryl and Israel Englander Institute for Precision Medicine1
  • Foundation for the Finnish Cancer Institute1
  • Sandra and Edward Meyer Cancer Center1
  • School of Medicine1
  • The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine1
  • Tisch Cancer Institute1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.